The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Single subretinal administration
University of Campania Luigi Vanvitelli
Naples, Italy
RECRUITINGMoorfields Eye Hospital
London, United Kingdom
RECRUITINGRetina Clinic London
London, United Kingdom
RECRUITINGTo measure the number and severity of treatment related adverse events following treatment with AAVB-081
Time frame: 61 months
Change from baseline in microperimetry following treatment with AAVB-081
Time frame: 61 months
Change from baseline in static perimetry following treatment with AAVB-081
Time frame: 61 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.